Evidence map›Paper›PMID 35538133›Full record

ArticleScientific reports2022

Radiobiological effects of wound fluid on breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic culture.

Shabnam Jeibouei, Ali Hojat, Ebrahim Mostafavi, Amir Reza Aref, Alireza Kalbasi, Vahid Niazi, Mohammad Ajoudanian, Farzaneh Mohammadi, Fariba Saadati, Seyed Mohammadreza Javadi and 7 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Shabnam Jeibouei *Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ali Hojat *Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ebrahim MostafaviStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, USA.
Amir Reza ArefXsphera Biosciences Inc., 6 Tide street, Boston, USA.
Alireza KalbasiBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Vahid NiaziDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad AjoudanianDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farzaneh MohammadiDepartment of Biology, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Fariba SaadatiZIK Plasmatis, Leibniz Institute for Plasma Science and Technology (INP), Greifswald, Germany.
Seyed Mohammadreza JavadiDepartment of Surgery, School of Medicine, Besat Hospital, Hamadan University of Medical Sciences, Hamadan, Iran.
Forough ShamsDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam MoghaddamDepartment of Molecular and Cell Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Farshid KaramiDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Kazem SharifiDepartment of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farid MoradianShohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad Esmaeil AkbariCancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. profmeakbari@gmail.com.
Hakimeh ZaliDepartment of Tissue Engineering and Applied Cell Sciences, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. h.zali@sbmu.ac.ir.
Shahid Beheshti University of Medical Sciences · IRBrigham and Women's Hospital · USCardiovascular Institute of the South · USDana-Farber Cancer Institute · USHamedan University of Medical Sciences · IRIslamic Azad University Central Tehran Branch · IRLeibniz Institute for Plasma Science and Technology · DEShahid Beheshti University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intraoperative radiotherapy (IORT) could abrogate cancer recurrences, but the underlying mechanisms are unclear. To clarify the effects of IORT-induced wound fluid on tumor progression, we treated breast cancer cell lines and human-derived tumor spheroids in 2D and microfluidic cell culture systems, respectively. The viability, migration, and invasion of the cells under treatment of IORT-induced wound fluid (WF-RT) and the cells under surgery-induced wound fluid (WF) were compared. Our findings showed that cell viability was increased in spheroids under both WF treatments, whereas viability of the cell lines depended on the type of cells and incubation times. Both WFs significantly increased sub-G1 and arrested the cells in G0/G1 phases associated with increased P16 and P21 expression levels. The expression level of Caspase 3 in both cell culture systems and for both WF-treated groups was significantly increased. Furthermore, our results revealed that although the migration was increased in both systems of WF-treated cells compared to cell culture media-treated cells, E-cadherin expression was significantly increased only in the WF-RT group. In conclusion, WF-RT could not effectively inhibit tumor progression in an ex vivo tumor-on-chip model. Moreover, our data suggest that a microfluidic system could be a suitable 3D system to mimic in vivo tumor conditions than 2D cell culture.

Indexed as

Breast NeoplasmsSurgical WoundCell Culture TechniquesCell Line, TumorFemaleHumansMCF-7 CellsMicrofluidicsNeoplasm Recurrence, LocalSpheroids, Cellular

Identifiers

PMID35538133
PMCPMC9091274
OpenAlexW4280490808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.